Nurix Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer,...
Latest News
5 days ago · globenewswire.com
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerPhysician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions
6 days ago · globenewswire.com
Nurix Therapeutics to Participate in Upcoming Investor ConferencesBRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference Tuesday, November 17, 2026, at 2:40 p.m.
1 month ago · seekingalpha.com
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement PathwaysNurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.
1 month ago · zacks.com
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.
1 month ago · globenewswire.com
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
1 month ago · globenewswire.com
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaFirst patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
1 month ago · globenewswire.com
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesTwo-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by an additional two years.
2 months ago · seekingalpha.com
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptNurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
2 months ago · seekingalpha.com
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptNurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · zacks.com
Here's Why You Should Add NRIX Stock to Your Portfolio NowNurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NRIX